Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|10 CitationsCognitive & SleepFemale-friendly

PE-22-28 Dosing Protocol: Neuroplasticity Guide

Also known as: TREK-1 Inhibitor Heptapeptide, Spadin Analog

Dose Range
100–500 mcgResearch range
0Typical research window: 100–500 mcg600 mcg

Studied in published research — not a medical recommendation. Primary protocol (Cognitive/Antidepressant Protocol): 100-500 mcg, Daily or twice daily.

Protocol at a Glance
How Often
1–2× daily

Daily or twice daily

A Typical Run
4-8 weeks

Research-reported range (no primary dosing study). Preclinical studies show rapid antidepressant effects

How It's Taken
Vial

Subcutaneous injection or intranasal

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 100 mcg4 units
High end: 500 mcg20 units

All U-100: 100 units = 1 mL. 50 doses in the vial at the low end (10 doses at the high end).

Track the doses you run

Save PE-22-28 (Mini-Spadin) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

PE-22-28 (Mini-Spadin) supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$60.00
10mg vial
$6.00/mg
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$30.00
5mg vial
$6.00/mg
Core Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$54.00
8mg vial
$6.75/mg
Biotech Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$55.00
8mg vial
$6.88/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$120.00
10mg vial
$12.00/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Research / Non-FDATier 3 — Translational Animal & Clinical Obs
Pharmacological Class
Neurotrophic & Neuroregulatory Neuropeptide (BDNF / NGF / GABA Modulator)
Administration Route
Intranasal spray (mucosal BBB delivery) or Under-the-skin injection (SubQ)
2026 FDA & 503A Status
Unapproved investigational compound in the US; not listed on the FDA 503A Bulk Drug Substances positive list. Available for laboratory research with third-party HPLC + LC-MS COA verification.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 3 — Translational Animal & Clinical Obs: Replicated mammalian preclinical models plus extensive off-label physician & community protocol tracking
What is a Nootropic Peptide?

A peptide that enhances cognitive function — memory, focus, learning, or neuroprotection. Unlike synthetic nootropics (racetams, modafinil), peptide nootropics work through neurotrophic factors like BDNF and NGF. Examples: Semax, Selank, Dihexa, PE-22-28. Most were developed in Russian neuroscience labs.

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. PE-22-28 (Mini-Spadin) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

PE-22-28 is a synthetic peptide derived from the neuroprotective drug tianeptine. It represents the active pharmacophore responsible for tianeptine's neuroplasticity-enhancing effects.

Mechanisms of Action

  • Modulates glutamate receptor activity (AMPA/NMDA)
  • Enhances brain-derived neurotrophic factor (BDNF) expression
  • Promotes neuroplasticity and synaptic remodeling
  • Fast-acting antidepressant-like effects

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Cognitive/Antidepressant Protocol
reported protocol
100-500 mcgDaily or twice daily4-8 weeksSubcutaneous injection or intranasalanimal—
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (PE-22-28 (Mini-Spadin))

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

5 Human5 Animal

Despite the large number of available studies, a high clinical, statistical, and methodological heterogeneity was observed. More methodologically rigorous studies are needed to clarify the effectiveness of each protocol and modality of intervention.

Limitations: No placebo control reported. Review article — no new primary data.

2025|GeroScience
PubMed

From 89 studies (mean follow-up: 5.2 years), conversion risk was 41.5% (38.3%-44.7%) in clinical and 27.0% (22.0%-32.0%) in population-based studies, with Alzheimer's dementia as the most common outcome. Stability rates were 49.3% (clinical) and 49.8% (population).

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2025|Alzheimer's &amp; dementia (Amsterdam, Netherlands)
PubMed

Finally, our findings revealed that mice lacking TREK-1 gained more fat mass and had worse glucose tolerance when fed a high-fat diet (HFD) compared to the wild-type controls. The findings demonstrate that increase of the membrane potential at adipocytes through the downregulation of TREK-1 can influence the progression of adipogenesis.

Limitations: Animal study only — human translation uncertain.

2025|Cell death &amp; disease
PubMed

The literature review for this guideline included studies published up to November 2023. More than 1000 peer-reviewed publications were included, covering the following.

Limitations: No placebo control reported.

2024|Age and ageing
PubMed

The CCDDs using a Minimum Core Test (MCT) significantly increased from 45.7% in 2015 to the current 57.1%. Territorial CCDDs using MCT significantly increased from 24.9% in 2015 to 37% in 2022 (p&#x2009;=&#x2009;0.004).

Limitations: No placebo control reported.

2024|Aging clinical and experimental research
PubMed

In addition, Mini-Spadin promotes beta-cell proliferation, suggesting its possible regenerative effect. This study highlights new possible roles of PE in pancreatic beta-cell survival and its derivatives as pharmacological tools against diabetes.

Limitations: Animal study only — human translation uncertain.

2022|Pharmacological research
PubMed

Finally, enhanced neurogenesis and synaptogenesis contributed to the beneficial effects of mini-spadin against stroke and PSD. This work reveals the first evidence that the modulation of TREK-1 channels in the early and chronic phases of stroke as well as the stimulation of brain plasticity by mini-spadin could play a key role in its brain protective effects against stroke and its deleterious consequences such as PSD.

Limitations: No placebo control reported.

2020|Neuropharmacology
PubMed

Shortened spadin analogs present increased inhibition potency for TREK-1, an improved AD activity, and prolonged in vivo bioavailability. Finally, we also discuss about other inhibitors of TREK-1 channels with a proven efficacy in treating depression in the clinic, such as fluoxetine.

Limitations: No placebo control reported. Review article — no new primary data.

2020|Pharmacology &amp; therapeutics
PubMed

Finally, the action duration of PE 22-28 and its analogs was largely improved in comparison with that of spadin, up to 23 h instead of 7 h. Taken together, our results demonstrated that PE 22-28 and its derivatives represent other promising molecules that could be an alternative to spadin in the treatment of depression.

Limitations: Animal study only — human translation uncertain.

2020|Frontiers in pharmacology
PubMed

As a putative bioactive peptide, we have evaluated its autocrine effect by the use of spadin on 3T3-L1 adipocytes by performing glucose uptake and signalling experiments. Any effect was measured on adipocytes indicating that the use of spadin as an antidepressant would have no side effects on adipocyte physiology.

Limitations: Animal study only — human translation uncertain.

2017|Biochemical and biophysical research communications
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Limited safety data; research use only
  • •May affect mood significantly - use with caution
  • •Not FDA approved
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get PE-22-28 (Mini-Spadin), baseline labs & clinician oversight.

Full PE-22-28 (Mini-Spadin) $/mg comparison →
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy PE-22-28 (Mini-Spadin): best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Elite Research USA — $6.00/mg (10mg vial, $60.00)
  2. 2. Pure Peptides — $6.00/mg (5mg vial, $30.00)
  3. 3. Core Peptides — $6.75/mg (8mg vial, $54.00)

Where is the cheapest place to buy PE-22-28 (Mini-Spadin)?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Elite Research USA at $6.00/mg (10mg vial, $60.00). We compared 5 US suppliers with live, checked prices.

How much does PE-22-28 (Mini-Spadin) cost per mg?

Verified US domestic prices currently range from $6.00/mg to $12.00/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is PE-22-28 (Mini-Spadin) approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Trusted Voices

X/Twitter accounts discussing this peptide

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.